{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Prophylactic+Regimen+A", "query": { "intervention": "Prophylactic Regimen A" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 101, "total_pages": 11, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Prophylactic+Regimen+A&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-25T03:13:45.846Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01262560", "title": "Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dysphagia", "Lung Cancer", "Pain", "Esophagitis" ], "interventions": [ { "name": "Manuka honey in liquid form", "type": "DRUG" }, { "name": "Manuka honey in lozenge form", "type": "DRUG" }, { "name": "Standard supportive care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 163, "start_date": "2012-02", "completion_date": "2014-11", "has_results": true, "last_update_posted_date": "2017-08-31", "last_synced_at": "2026-09-25T03:13:45.846Z", "location_count": 59, "location_summary": "Mobile, Alabama • San Francisco, California • Stanford, California + 50 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01262560" }, { "nct_id": "NCT01971853", "title": "Does Preventive Analgesia Improve the Outcome of Demerol-Vistaril Procedural Sedations in Pediatric Dentistry", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pain" ], "interventions": [ { "name": "oral placebo", "type": "DRUG" }, { "name": "Oral Analgesics", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "2 Years", "maximum_age": "8 Years", "sex": "ALL", "summary": "2 Years to 8 Years" }, "enrollment_count": 88, "start_date": "2013-10", "completion_date": "2016-12-31", "has_results": true, "last_update_posted_date": "2021-01-22", "last_synced_at": "2026-09-25T03:13:45.846Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01971853" }, { "nct_id": "NCT02608879", "title": "Oral Care Protocol for the Management of Chemotherapy and Radiation Therapy-Induced Oral Mucositis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Oral Mucositis", "Oral Cancer" ], "interventions": [ { "name": "Oral Mucosa Deterging and Periodontal Debridement (OMDP)", "type": "PROCEDURE" }, { "name": "Standard of Care Oral Hygiene Instructions", "type": "PROCEDURE" }, { "name": "Dental scaling, ultrasonic", "type": "PROCEDURE" }, { "name": "Chlorhexidine", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2014-03", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2020-08-28", "last_synced_at": "2026-09-25T03:13:45.846Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02608879" }, { "nct_id": "NCT01985126", "title": "An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Daratumumab 16 mg/kg (Part 1)", "type": "DRUG" }, { "name": "Daratumumab 8 mg/kg (Part 1)", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Daratumumab (Part 2)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 124, "start_date": "2013-09-27", "completion_date": "2017-05-30", "has_results": true, "last_update_posted_date": "2018-06-25", "last_synced_at": "2026-09-25T03:13:45.846Z", "location_count": 15, "location_summary": "Duarte, California • Los Angeles, California • Atlanta, Georgia + 12 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01985126" }, { "nct_id": "NCT00002610", "title": "Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "dactinomycin", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 203, "start_date": "1996-01", "completion_date": "2006-02", "has_results": false, "last_update_posted_date": "2014-07-25", "last_synced_at": "2026-09-25T03:13:45.846Z", "location_count": 206, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002610" }, { "nct_id": "NCT00801697", "title": "Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "DNA Vaccine", "type": "BIOLOGICAL" }, { "name": "DNA Vaccine placebo", "type": "BIOLOGICAL" }, { "name": "rAd35", "type": "BIOLOGICAL" }, { "name": "rAd35 placebo", "type": "BIOLOGICAL" }, { "name": "rAd5", "type": "BIOLOGICAL" }, { "name": "rAd5 placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 192, "start_date": "2009-02", "completion_date": "2015-04", "has_results": false, "last_update_posted_date": "2021-10-14", "last_synced_at": "2026-09-25T03:13:45.846Z", "location_count": 10, "location_summary": "Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00801697" }, { "nct_id": "NCT02598388", "title": "Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hemorrhagic Fever, Ebola" ], "interventions": [ { "name": "Ad26.ZEBOV", "type": "BIOLOGICAL" }, { "name": "MVA-BN-Filo", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Janssen Vaccines & Prevention B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 578, "start_date": "2015-12-10", "completion_date": "2018-12-12", "has_results": true, "last_update_posted_date": "2025-02-04", "last_synced_at": "2026-09-25T03:13:45.846Z", "location_count": 1, "location_summary": "Silver Spring, Maryland", "locations": [ { "city": "Silver Spring", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02598388" }, { "nct_id": "NCT05243056", "title": "A Quality of Life Intervention for Young African American Breast Cancer Survivors in Treatment", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage IA Breast Cancer AJCC v8", "Anatomic Stage IB Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage IIA Breast Cancer AJCC v8", "Anatomic Stage IIB Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Prognostic Stage I Breast Cancer AJCC v8", "Prognostic Stage IA Breast Cancer AJCC v8", "Prognostic Stage IB Breast Cancer AJCC v8", "Prognostic Stage II Breast Cancer AJCC v8", "Prognostic Stage IIA Breast Cancer AJCC v8", "Prognostic Stage IIB Breast Cancer AJCC v8", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Educational Intervention", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "44 Years", "sex": "FEMALE", "summary": "18 Years to 44 Years · Female only" }, "enrollment_count": 37, "start_date": "2022-06-01", "completion_date": "2025-12-30", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-09-25T03:13:45.846Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT05243056" }, { "nct_id": "NCT02057770", "title": "Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, Myeloid, Acute" ], "interventions": [ { "name": "busulfan", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "total-body irradiation (TBI)", "type": "RADIATION" }, { "name": "Stem cell transplant", "type": "PROCEDURE" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2014-02-28", "completion_date": "2018-03-23", "has_results": false, "last_update_posted_date": "2018-10-12", "last_synced_at": "2026-09-25T03:13:45.846Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02057770" }, { "nct_id": "NCT00360685", "title": "Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Mucositis", "Graft-versus-host Disease" ], "interventions": [ { "name": "Tac+MTX", "type": "DRUG" }, { "name": "TAC + MMF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 89, "start_date": "2005-09", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2013-05-03", "last_synced_at": "2026-09-25T03:13:45.846Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00360685" } ] }